Arthritis Research

Arthritis is an inflammatory disease of the joints, including the synovium, cartilage, bone, and supporting tissues. It is the leading cause of disability in the US and there are over 100 different types of the disease. The most common types of arthritis are osteoarthritis, rheumatoid arthritis and gout.

Arthritis Research Products Targets

Products for Arthritis Research - Page 8

Cat.No. Product Name Information/Activity
BCC7725 SU 3327 SU3327 is a potent, selective and substrate-competitive JNK inhibitor with an IC50 of 0.7 μM. SU3327 also inhibits protein-protein interactions between JNK and JNK Interacting Protein (JIP) with an IC50 of 239 nM. SU3327 shows less active against p38α and Akt kinase.
BCC5148 TCS JNK 5a TCS JNK 5a is a potent JNK3 inhibitor with a pIC50 of 6.7. TCS JNK 5a also inhibits JNK2 with a pIC50 of 6.5.
BCC7607 TCS JNK 6o JNK Inhibitor VIII (TCS JNK 6o) is a c-Jun N-terminal kinases (JNK-1, -2, and -3) inhibitor with Ki values of 2 nM, 4 nM, 52 nM, respectively, and has IC50 values of 45 nM and 160 nM for JNK-1 and -2, respectively.
BCC7007 Anisomycin Anisomycin is a potent protein synthesis inhibitor which interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. Anisomycin is a JNK activator, which increases phospho-JNK. Anisomycin is a bacterial antibiotic isolated from Streptomyces griseolus.
BCC7576 BAY-u 9773 Dual CysLT1 and CysLT2 antagonist
BCC7244 Cinalukast 128312-51-6
BCC7310 FPL 55712 40785-97-5
BCC7334 MK 571 MRP1 inhibitor; also CysLT1 (LTD4) inverse agonist
BCC4680 Montelukast Sodium Montelukast (sodium) (MK0476) is a potent, selective CysLT1 receptor antagonist.
BCC4827 Pranlukast Pranlukast is a highly potent, selective and competitive antagonist of peptide leukotrienes. Pranlukast inhibits [3H]LTE4, [3H]LTD4, and [3H]LTC4 bindings to lung membranes with Kis of 0.63±0.11, 0.99±0.19, and 5640±680 nM, respectively.